Structure Therapeutics Incorporation header image

Structure Therapeutics Incorporation

GPCR

Equity

ISIN null / Valor 124807608

NASDAQ (2026-03-05)
USD 59.70-5.43%

Structure Therapeutics Incorporation
UMushroom community rating:

star star star star star
3.38 8 votes No rating yet
NegativeNeutralPositive

About company

Structure Therapeutics Incorporation leverages advanced technologies in molecular visualization, computational chemistry, and data integration to develop innovative medicines. The company focuses on creating oral small molecule drugs that aim to achieve the efficacy and specificity typically associated with biologic and peptide drugs, while addressing the limitations inherent to these traditional therapies. By integrating cutting-edge scientific techniques, Structure Therapeutics seeks to provide differentiated therapeutic solutions that enhance patient outcomes.

Summarized from source with an LLMView SourceSector: Finance

Latest Results ():

Summarized from source with an LLMView Source

Key figures

165%1Y
125%3Y
%5Y

Performance

101%1Y
93.2%3Y
92.9%5Y

Volatility

Market cap

4229 M

Market cap (USD)

Daily traded volume (Shares)

811,998

Daily traded volume (Shares)

1 day high/low

28.72 / 26.04

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.38

8 votes
Performance:
starstarstarstarstar
2.75
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
3.75
Nature:
starstarstarstarstar
3.50
Bastien Romanens
Switzerland, 02 Nov 2025
star star star star star
-
Virgil Zhu
United Kingdom, 27 Oct 2025
star star star star star
really depends on the news about clinical trials
****** Panggabean
United Kingdom, 26 Oct 2025
star star star star star
Strong innovation and a solid cash position, but the stock has been under pressure as R&D costs rise and profitability remains distant. The company’s GLP-1 pipeline offers promise, yet market sentiment reflects uncertainty about near-term returns.

EQUITIES OF THE SAME SECTOR

Aroundtown SA
Aroundtown SA Aroundtown SA Valor: 38311137
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.77%EUR 2.59
ENCAVIS AG
ENCAVIS AG ENCAVIS AG Valor: 923850
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.11%EUR 17.60
Gateway Real Estate AG
Gateway Real Estate AG Gateway Real Estate AG Valor: 2560486
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 0.34
Hufvudstaden AB
Hufvudstaden AB Hufvudstaden AB Valor: 613766
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.10%SEK 126.40
Power Corp of Canada
Power Corp of Canada Power Corp of Canada Valor: 697834
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.29%CAD 69.49
Vipshop Holdings Ltd
Vipshop Holdings Ltd Vipshop Holdings Ltd Valor: 18178564
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.08%USD 15.97
InCity Immobilien AG
InCity Immobilien AG InCity Immobilien AG Valor: 2988577
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
20.00%EUR 0.48
capsensixx AG
capsensixx AG capsensixx AG Valor: 42196898
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.65%EUR 22.00
MHP Hotel AG
MHP Hotel AG MHP Hotel AG Valor: 113213275
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%EUR 1.43
ERWE Immobilien AG
ERWE Immobilien AG ERWE Immobilien AG Valor: 22276119
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.94%EUR 0.32